Denosumab in breast cancer

Allan Lipton

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Bone destruction is mediated by osteoclasts, whose formation, function, and survival requires the receptor activator of NF-kB ligand (RANKL). Denosumab is a fully human monoclonal antibody to RANKL, thereby inhibiting osteoclast-mediated bone destruction, and blocks the vicious cycle of cancer-mediated bone disease. In breast cancer patients with bone metastases, denosumab was superior to zoledronic acid in delaying time to first on-study skeletal-related event (SRE; HR∈=∈0.82; P∈=∈0.01 superiority) and time to first and subsequent on-study SREs (HR∈=∈0. 77; P∈=∈0.001). Overall survival, disease progression, and serious adverse events were similar between groups.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalCurrent oncology reports
Issue number1
StatePublished - Feb 2011

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'Denosumab in breast cancer'. Together they form a unique fingerprint.

Cite this